Fagron N.V. (ARSUF)
Fagron N.V. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Nazareth, VL, BE. The stock last traded at $27.50, up 0.00% on the session, giving a market capitalisation of $2.02B. On trailing twelve-month figures it carries a trailing P/E of 17.84, a net margin of 8.9%. Its beta of 0.39 implies it has historically moved less than the broad market.
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.
Fagron N.V. is most often compared with the following Healthcare names: